Glomerulopathy
Drug research and approvals for glomerulopathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 34 studies of glomerulopathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, FDA has 3 approved and 3 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 34
- Trials authorized in Canada: 5
- FDA orphan approvals: 3
- EU medicines: 1
- Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort StudyNCT07931170 · Not reported · Pediatric Nephrology Research Consortium · starts Oct 1, 2026
- Dermal Priming in Enhancing Vaccine ImmunogenicityNCT07925996 · Not applicable · Cambridge University Hospitals NHS Foundation Trust · starts Dec 15, 2025
- A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in…NCT07898774 · Phase 3 · Swedish Orphan Biovitrum · starts Jan 21, 2027
- Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country StudyNCT07746895 · Phase 4 · Swedish Orphan Biovitrum · starts Aug 5, 2026
- Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected…NCT07614477 · Phase 2 · Everest Medicines (China) Co.,Ltd. · starts May 20, 2026
- A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in SpainNCT07598448 · Not reported · Novartis Pharmaceuticals · starts Sep 22, 2026
- Chinese Adults With Kidney DiseaseNCT07522099 · Phase 2 · ADARx Pharmaceuticals, Inc. · starts May 21, 2026
- Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With…NCT07498335 · Phase 3 · Novartis Pharmaceuticals · starts Aug 6, 2026
- A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients…NCT07483827 · Phase 1 · eleva GmbH · starts Jun 26, 2025
| Jul 28, 2026 | A 2-year, single-arm, multi-center study to explore the efficacy and safety of pegcetacoplan in preventing disease recurrence in adolescent and adult kidney…Pegcetacoplan (APL-2) | Swedish Orphan Biovitrum | Pending |
| Sep 12, 2023 | An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan (LNP023) in C3 glomerulopathy or…Iptacopan (LNP023) | Novartis Pharmaceuticals | Ongoing |
| May 18, 2022 | A phase 3, randomized, placebo-controlled, double-blinded, multicenter study to evaluate the efficacy and safety of pegcetacoplan in patients with C3…Pegcetacoplan (APL-2) | Apellis Pharmaceuticals | Closed |
| Jun 9, 2021 | A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3…Iptacopan (LNP023) | Novartis Pharmaceuticals | Ongoing |
| Dec 13, 2017 | A randomized, double-blind, placebo-controlled phase 2 study to evaluate the safety and efficacy of avacopan (CCX168) in patients with C3 glomerulopathyAvacopan (CCX168) | Amgen | Closed |
| Aug 20, 2026 | EmpaveliTreatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G), to reduce proteinuria and the loss of… | Apellis Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen, MA, Inc. | Approved |
| Jul 28, 2025 | EmpaveliTreatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G), to reduce proteinuria | Apellis Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen, MA, Inc. | Approved |
| Mar 20, 2025 | FabhaltaTreatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria | Novartis Pharmaceuticals Corporation | Approved |
| Oct 16, 2025 | Chemically synthesized double-stranded oligonucleotide…Treatment of complement 3 glomerulopathy | Sanegene Bio USA Inc. | Designated |
| Nov 22, 2022 | Synthetic double-strand small interfering ribonucleic acid…Treatment of C3 Glomerulopathy | Silence Therapeutics plc | Designated |
| Nov 16, 2015 | S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-me…Treatment of C3 glomerulopathy. | Amyndas Pharmaceuticals S.A | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| May 17, 2024 | FabhaltaIptacopan · orphan | Novartis Europharm Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA